SmithJAMedinaPMiaoM, et al.A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer. Am J Health Syst Pharm2025; 82: 522–536. PMID: 40126684; PMCID: PMC12094874.
2.
Elahere (mirvetuximab soravtansine injection) package insert. IMMUNOGEN INC. 03/22/2024.
3.
Center for Drug Evaluation and Research, Food and Drug Administration. Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products—Content and Format Guidance for Industry. Food and Drug Administration; 2023. www.fda.gov/media/72142/download (accessed 07/08/2025).
TuYPLagraauwHMMethodM, et al.Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: justification of therapeutic dose regimen. Br J Clin Pharmacol2025 Jan; 91: 220–231. Epub 2024 Sep 22. PMID: 39307840.
6.
MooreKNBorghaeiHMalleyO, et al.Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer2017; 123: 3080–3087. Epub 2017 Apr 25. PMID: 28440955; PMCID: PMC6896318.
7.
TuYPHanzeEZhuF, et al.Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: the antibody-drug conjugate, payload and metabolite. Br J Clin Pharmacol2024 Feb; 90: 568–581. Epub 2023 Nov 13. PMID: 37872122.
8.
ChichesterSHolmesTMHubbardJ. Ideal body weight: a commentary. Clin Nutr ESPEN2021 Dec; 46: 246–250. Epub 2021 Oct 12. PMID: 34857204; PMCID: PMC8646317.
9.
PaiMPPaloucekFP. The origin of the “ideal” body weight equations. Ann Pharmacother2000 Sep; 34: 1066–1069. PMID: 10981254.
10.
FieldKMKosmiderSJeffordM, et al.Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract2008; 4: 108–113. PMID: 20856612; PMCID: PMC2794002.
11.
FahrenbruchRKintzelPBottAM, et al.Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the hematology/oncology pharmacy association. J Oncol Pract2018 Mar; 14: e130–e136. Epub 2018 Feb 5. PMID: 29400987.
12.
DilawariAShahMIsonG, et al.FDA Approval summary: mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant ovarian cancer. Clin Cancer Res2023 Oct 2; 29: 3835–3840. PMID: 37212825; PMCID: PMC10592645.
13.
BertonMBettonteSStaderF, et al.Repository describing the anatomical, physiological, and biological changes in an obese population to inform physiologically based pharmacokinetic models. Clin Pharmacokinet2022 Sep; 61: 1251–1270. Epub 2022 Jun 14. PMID: 35699913; PMCID: PMC9439993.
14.
PaiMP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy2012 Sep; 32: 856–868. Epub 2012 Jun 18. PMID: 22711238.
15.
BossiPDelrioPMascheroniA, et al.The Spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients2021 Jun 9; 13: 1980. PMID: 34207529; PMCID: PMC8226689.
16.
LedermannJACanevariSThigpenT. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol2015 Oct; 26: 2034–2043. Epub 2015 Jun 10. PMID: 26063635.
17.
CahillMClearyBJCullinanS. The influence of electronic health record design on usability and medication safety: systematic review. BMC Health Serv Res2025 Jan 6; 25: 31. PMID: 39762805; PMCID: PMC11705737.
